IFNA1 and hepatocellular carcinoma: Similarly, Nagata et al. demonstrated that the 3-year cumulative incidence of HCC occurrence in patients with SVR did not differ by therapy in propensity score-matched analysis (3.3% for IFN-based, 1.4% for IFN-free therapy; P = 0.49, log-rank test)28.